All In Biotech

Drug Trial Radar · NCT05355207

Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis

Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TRL1068 in Subjects With Acute Exacerbation of Chronic Rhinosinusitis

Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

12

Planned (sponsor's estimate)

Start

Jan 2024

Primary completion

Jan 2025

Study completion Jan 2025

Sponsor

Lead sponsor
Trellis Bioscience LLCIndustry
Sponsor type
Industry
First posted
May 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TRL1068 is expected to eliminate the pathogen-protecting biofilm in Chronic Rhinosinusitis, thus making these bacteria substantially more susceptible to established antibiotic treatment regimens. This initial study is to assess overall safety and pharmacokinetics (PK) of TRL1068. The goal of the development program is to demonstrate effectiveness of TRL1068 in difficult to treat bacterial infections such as in CRS.

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps

Interventions

  • TRL1068Drug

    A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of abnormal physical exam findingsTime frame: 6 weeks
  2. Incidence of abnormal serum chemistries and hematologyTime frame: 6 weeks
  3. Incidence of abnormal vital signs (temperature)Time frame: 6 weeks
  4. Incidence of abnormal vital signs (blood pressure)Time frame: 6 weeks
  5. Incidence of abnormal vital signs (heart rate)Time frame: 6 weeks
  6. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 7 weeks
  7. Characterize the pharmacokinetics (PK) of TRL1068 in serum (Cmax)Time frame: 6 weeks
  8. Characterize the pharmacokinetics (PK) of TRL1068 in serum (Cmin)Time frame: 6 weeks
  9. Characterize the pharmacokinetics (PK) of TRL1068 in serum (Tmax)Time frame: 6 weeks
  10. Characterize the pharmacokinetics (PK) of TRL1068 in serum (AUCLAST)Time frame: 6 weeks
  11. Characterize the pharmacokinetics (PK) of TRL1068 in serum (AUCINF)Time frame: 6 weeks
  12. Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (Cmax)Time frame: 6 weeks
  13. Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (Cmin)Time frame: 6 weeks
  14. Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (Tmax)Time frame: 6 weeks
  15. Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (AUCLAST)Time frame: 6 weeks
  16. Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (AUCINF)Time frame: 6 weeks
  17. Characterize the pharmacodynamics (PD) of TRL1068 (time to resolution of bacterial pathogen infection)Time frame: 6 weeks
  18. Characterize the pharmacodynamics (PD) of TRL1068 (time to resolution of signs and symptoms of acute exacerbation)Time frame: 6 weeks
  19. Assess the immunogenicity of TRL1068 as measured by anti-drug antibodies (ADAs)Time frame: 6 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.